Evidence map›Paper›PMID 39886589›Full record

ReviewJACS Au2025

Abraham Patchornik: The Contemporary Relevance of His Work for Chemistry and Biology.

Kenneth A Jacobson, Graham C R Ellis-Davies

Abstract readReview
In one paragraph

Review in JACS Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Bitopic AJournal of medicinal chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kenneth A JacobsonLaboratory of Bioorganic Chemistry, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.ORCID https://orcid.org/0000-0001-8104-1493
Graham C R Ellis-DaviesDepartment of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.ORCID https://orcid.org/0000-0003-4179-5455

Funding

Development Of Drugs Acting At Adenosine ReceptorsZIADK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$10.4M
Light-Driven Control of Neurons in Vitro and in VivoR35NS111600 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Graham Ellis-Davies · 2019 to 2026
$5.5M
Intramural NIH HHS ZIA DK031117NINDS NIH HHS R35 NS111600
6 · The paper itself

Abstract

Abraham Patchornik was born in 1926 in Ness Ziona, a town in Palestine founded by his great-grandfather Reuben Lehrer in 1883. He started to study chemistry as an undergraduate at the Hebrew University. However, this was interrupted by the war, and he completed his studies in various locations in West Jerusalem. From 1952 to 1956 Patchornik completed his PhD at the (new) Weizmann Institute of Science with Ephraim Katchalski. After a postdoc at the NIH, he returned to the Weizmann in 1958, when he joined the Department of Biophysics. In 1972-1979, he became chairman of the new Department of Organic Chemistry at the Weizmann, and his own research was geared toward applying creative chemistry to solve biological problems. Patchornik passed away in his hometown of Ness Ziona in 2014. Patchornik was a conceptual leader in peptide and polymer chemistry. Given the importance of selective functional group protection for the construction of oligomeric molecules, he became interested in using "nonstandard", orthogonal chemistry for this purpose, i.e. photosensitive protecting groups (PPGs) in place of thermal reactions. It was R.B. Woodward who suggested this strategy to Patchornik in 1965, while Patchornik was on sabbatical leave at Harvard. However, it was not until Patchornik returned to the Weizmann that this idea of a versatile PPG to enable multistep synthesis was realized. Here, we provide an account of the early photosensitive protecting groups that Patchornik and co-workers developed, and the immense impact they have had on various fields. In particular, we survey the use of PPGs in live cell physiology (i.e., caged compounds), and the development of gene chips via light-directed solid-phase synthesis. Further, we highlight recent work applying new PPGs for "photochemical delivery" of drugs, otherwise termed photopharmacology. Finally, we discuss the relationship between caged compounds and how contemporary neuroscience uses genetically encoded chromophores to control cell function.

Identifiers

PMID39886589
PMCPMC11775701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.